Drug intelligence / Profile preview

instant MSC product + autologous chondrocytes

Development stage
Unknown
Lead developer
University Medical Center Utrecht
Modality
Cell Therapies
Administration
Intraarticular
01

Overview

IMPACT (Instant MSC Product accompanying Autologous Chondron Transplantation) is a combined cell therapy developed by the University Medical Center Utrecht for the treatment of focal articular cartilage defects in the knee. The product consists of a combination of allogeneic, bone marrow-derived mesenchymal stromal cells (MSCs) and autologous chondrons (chondrocytes with their native pericellular matrix) isolated from the patient's own debrided cartilage. Administered in a single-stage surgical procedure, the allogeneic MSCs act as trophic signaling units that stimulate the autologous chondrons to regenerate hyaline-like cartilage tissue, rather than the MSCs themselves differentiating into cartilage. This approach aims to provide a rapid, one-step alternative to traditional two-stage autologous chondrocyte implantation (ACI) procedures.

Other names
IMPACTInstant MSC Product accompanying Autologous Chondron Transplantationallogeneic mesenchymal stromal cells + autologous chondrons

Beyond the preview

Go deeper on instant MSC product + autologous chondrocytes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on instant MSC product + autologous chondrocytes.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call